Neuronetics is trading at $2.42 (up 5%), extending a sharp rebound that began in late July and gained momentum in early August.
- The move appears driven by ongoing follow-through from recent strength in healthcare stocks and broader market risk-on sentiment.
- There are no fresh company-specific filings or news headlines today to account for the current price action.
- The stock's upward trajectory follows a period of accelerated gains previously observed on August 3–4.